



Amgen Canada

Amgen applies science and innovation to help fight serious illness and dramatically improve people's lives. With Canadian headquarters located in Mississauga's vibrant biomedical cluster, and a research facility in Burnaby, British Columbia, Amgen's Canadian affiliate has been an important contributor to Canada's biotechnology sector since 1991.

Amgen Canada serves patients throughout Canada by delivering vital medicines to them. In addition, Amgen contributes to the development of new therapies or new uses for existing medicines in partnership with many of Canada's leading healthcare, academic, research, government and patient organizations. Today, tens of thousands of Canadians use Amgen medicines every year, and thousands more are enrolling in Amgen clinical studies that deliver the next generation of innovation.

Commitment to Improve Canada's Healthcare System

As a global leader in developing and delivering breakthrough biologic medicines that improve the health and well-being of patients dealing with serious illnesses, Amgen is committed to working with Canada's federal and provincial governments and other stakeholders to develop practical, cost-effective and long-term ways to sustain and improve Canada's healthcare system. Biologic medicines have the ability to change the practice of medicine like never before, and Amgen welcomes the opportunity to work together with patients, doctors, industry, healthcare practitioners and government to find healthcare solutions that are in the best interests of all Canadians.

An Integral Part of the Canadian Economy

Amgen Canada understands the importance of its operations to the continuing growth and success of the bioscience industries in Canada. The company's efforts in clinical operations, sales and marketing and other areas play a part in strengthening the Greater Toronto Area biotechnology cluster of companies, government and educational institutions and in growing Canada's leadership in biotechnology. As the region's biosciences sector has grown, Amgen has grown its own business in Canada, creating over 400 new jobs and introducing innovative medicines to Canadian healthcare providers and patients.

Amgen British Columbia, one of several research facilities operated by Amgen, specializes in the discovery and development of human therapeutic antibodies. The research center, located in Burnaby, became part of Amgen with the acquisition of Abgenix Inc. in April 2006. It currently employs over 50 people, including research scientists and support staff.

QUICK FACTS

Locations

Mississauga, Ontario
Burnaby, British Columbia

Staff

Burnaby – Approx. 50
Mississauga – Approx. 200
Field employees across the country – Approx. 150

Key Functions

Burnaby

- Research and Development

Mississauga

- Scientific Affairs
- Commercial Operations
- Administrative Functions

Address/Phone

Amgen Canada
6775 Financial Drive
Mississauga, Ontario
Canada L5N 0A4
(800) 665-4273

Amgen British Columbia
7990 Enterprise Street
Burnaby, British Columbia
Canada V5A 1V7
(604) 676-8300

HISTORY IN CANADA

1991 – Amgen Canada founded in Mississauga

1992 – Launch of NEUPOGEN®

1999 – Launch of STEMGEN®

2002 – Launches of Aranesp® and Kineret®,
Amgen acquires Immunex, including
Enbrel®

2004 – Launch of Neulasta® and Sensipar®

2005 – Kepivance® approved for use in Canada

2006 – Amgen acquires Abgenix, Inc., including
its Burnaby R&D group

2008 – Launch of Vectibix®

2009 – Launch of Nplate®

2010 – Launch of Prolia®

2011 – Launch of XGEVA™

ILLUSTRATIVE LIST OF AMGEN CANADA PARTNERS

Inflammation

- Alliance for a Canadian Arthritis Program
- Arthritis Society (regional and national)
- Canadian Rheumatology Research Consortium
- Canadian Dermatology Association
- Canadian Skin Patient Alliance

Nephrology

- Canadian Society of Nephrology
- Kidney Foundation of Canada (regional and national)
- Canadian Association of Nephrology Nurses
- Research chairs, professorships and partnerships (such as at Université Laval, Ottawa Hospital Kidney Research Centre, University Health Network, Toronto, and McMaster University/St. Joseph's Health Care, Hamilton)

Oncology

- Canadian Assoc. of Nurses of Oncology
- Canadian Bone Marrow Transplant Group
- Lymphoma Foundation
- Ontario Cancer Research Network
- Colorectal Cancer Association of Canada
- The Campaign to Control Cancer
- The Cancer Advocacy Coalition

Bone Health

- Osteoporosis Canada
- SIGMA Canadian Menopause Society
- CARP (Canadian Association of Retired Persons)
- Society of Obstetricians and Gynaecologists of Canada

ABOUT AMGEN

Amgen (NASDAQ: AMGN) discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.ca.

Amgen Medicines Available in Canada

Oncology

Aranesp® (darbepoetin alfa)
Neulasta® (pegfilgrastim) and NEUPOGEN® (filgrastim)
Vectibix® (panitumumab)
XGEVA™ (denosumab)

Nephrology

Aranesp® (darbepoetin alfa)
Sensipar® (cinacalcet)

Rheumatology

Enbrel® (etanercept)

Dermatology

Enbrel® (etanercept)

Bone Health

Prolia® (denosumab)

Hematology

Nplate® (romiplostim)

Clinical Trials

Amgen Canada conducts significant numbers of clinical trials with leading academic research institutions, hospitals, and clinics throughout Canada. Amgen Canada's Development Operations team, working with colleagues around the world, participates in Amgen global clinical programs spanning phases 1-4 in nephrology, oncology, hematology, inflammation, bone health, cardiology, and metabolic disorders. Since 1991, more than 10,000 patients have enrolled in Amgen clinical trials in Canada. Currently some 2,000 Canadian patients are enrolled in more than 60 trials at about 500 centres across Canada. Those centres include major teaching hospitals as well as community-based sites. A complete list of Amgen's clinical trials can be found on www.clinicaltrials.gov.

Community Involvement

Amgen is proud to contribute to many philanthropic efforts at academic institutions, in hospitals, with patients and in the community. Amgen is committed to raising the value of science literacy in the community; attracting bright young minds into the field of science by helping educators to teach more effectively; and improving access to science resources for teachers, students and the community at large. Amgen also dedicates substantial resources to strengthen and enrich the community. Holding Hands, Amgen Canada's community philanthropy initiative, defines the core focus of the company's community involvement - to support programs that help bring local families in need closer to wellness as they navigate a complex healthcare system, through information, education and support.

The company supports nephrology research in Canada through a variety of fellowships and research chairs and funds research activities in rheumatoid arthritis, osteoporosis and related diseases, including the Canadian Arthritis Society Fellowship in Rheumatoid Arthritis. Amgen Canada also supports the Kidney Foundation of Canada's KRESCENT (Kidney Research Scientist Core Education and National Training) Program, which recruits and trains world-class kidney scientists in Canada. In cancer care, Amgen Canada supports education initiatives at the Lymphoma Foundation Canada, the Colorectal Cancer Association and Wellspring.

